Chikungunya Vaccines 2023
Chikungunya Vaccines 2023
Like many vaccines under clinical development, Chikungunya vaccine candidates investigate technologies, such as live-attenuated virus vaccines, inactivated viral vaccines, recombinant viral vaccines, chimeric-alphavirus candidates, DNA vaccines, and virus-like particles, which focus on optimizing the balance between immunogenicity and safety, says the World Health Organization (WHO). This article, published by NPJ Vaccines on August 18, 2023, summarizes the Coalition for Epidemics Preparedness Innovations (CEPI) efforts and strategic considerations for developing Chikungunya vaccines and ensuring equitable access for CHIKV endemic countries. The Pan American Health Organization (PAHO) issued an epidemiological alert in 2023 confirming chikungunya is considered a significant public health threat.
The U.S. Food and Drug Administration (FDA) has not approved a chikungunya virus preventive vaccine as of September 22, 2023. The global vaccine market against chikungunya is estimated to exceed $500 million annually by 2032.
U.S. CDC and Chikungunya Vaccines
At the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) meeting on June 22, 2023, Nicole Lindsey, MS, presented the Value of a Vaccine to prevent travel-related chikungunya for U.S. persons. And Susan Hills, MBBS, MTH, presented WORK GROUP PLANS AND TIMELINES. The initial timeline indicates a potential CDC authorization in mid-2024.
Previously, on February 23, 2023, ACIP presentations: Introduction, Dr. Beth Bell; Global epidemiology of Chikungunya, Dr. Susan Hills; Chikungunya in U.S. travelers, Ms. Nicole Lindsey; Persistent arthralgia following Chikungunya, Ms. Nicole Lindsey; Workgroup considerations, Ms. Nicole Lindsey. Previously on October 19, 2022, the ACIP reviewed the following presentations led by Beth Bell, MD, MPH Chair, ACIP Chikungunya Vaccines Work Group; OVERVIEW OF CHIKUNGUNYA AND CHIKUNGUNYA VACCINES; VLA1553 Chikungunya Vaccine Candidate; CDC WORKGROUP INTERPRETATION OF VACCINE DATA AND WORKGROUP PLANS AND TIMELINES. On June 23, 2022, the ACIP presentation by Dr. B Bell and Dr. S Hills: Overview of chikungunya and chikungunya vaccines; Plans and timeline for workgroup activities, offered relevant insights.
Chikungunya Vaccine Candidates 2023
VLA1553 is a monovalent, single-dose, live-attenuated vaccine candidate. VLA1553 has been assigned an FDA Prescription Drug User Fee Act review goal date at the end of 2023 and filed a regulatory application with Health Canada on May 30, 2023, or marketing approval and regulatory submission to the European Medicines Agency in 2023.
CHIKV-VLP vaccine candidate is licensed by the National Institute of Allergy and Infectious Diseases. CHIKV VLP (PXVX0317) received Fast Track designation from the U.S. FDA in May 2018 and launched phase 3 studies in 2022. CHIKV VLP is a CHIKV virus-like particle vaccine owned by Bavarian Nordic A/S, potentially launching the vaccine in 2025.
mRNA-1944 encodes a fully human IgG antibody isolated initially from the B cells of a patient with a prior history of potent immunity against Chikungunya infection.
CD8+ T cell CHIKV Adaptive Vaccine candidate. Inclusion of the ligandome into the vaccine construct will require the selection of eight to twelve peptides from amongst the CHIKV peptide set (ligandome), all of which meet several specific criteria. In vitro efficacy studies will then need to be completed.
The Access to Advanced Health Institute received an $18 million award from the National Institutes of Health to develop a temperature-stable, single-dose vaccine candidate for the chikungunya virus. The vaccine uses an innovative RNA platform technology.
Chikungunya Vaccine Market
Market Research Future announced on December 6, 2022, the Chikungunya vaccine market is expected to register a CAGR of 10.12% from 2022 to 2030.
Chikungunya outbreak news in 2023 is posted at this link.
Chikungunya Vaccine News 2023
August 3, 2023 - "This project will demonstrate the use of RNA vaccine technology to avoid some of the classic manufacturing challenges in the large-scale manufacture of live-attenuated vaccines," said Emily Voigt, Ph.D., Principal Scientist, AAHI RNA Platform Lead, and Co-Principal Investigator for the award.
February 2, 2023 - Merck confirmed to Fierce Biotech that it had discontinued the chikungunya vaccine program as part of a "routine pipeline prioritization."
November 28, 2022 - Emergex Vaccines Holding Limited announces that it has generated a Chikungunya ligandome, the first significant milestone in developing Emergex's CD8+ T cell CHIKV Adaptive Vaccine candidate.
February 22, 2022 - U.K.-based Emergex Vaccines Holding Limited announced it was awarded a £490,525 grant by the U.K. government's Department of Health and Social Care to advance a synthetic T-cell vaccine candidate for the Chikungunya virus.
September 12, 2019 - Moderna, Inc. announced positive data in the first analysis of safety and activity in its Phase 1 study evaluating escalating doses of mRNA-1944 administered via intravenous infusion in healthy adults. mRNA-1944 encodes for an antibody (CHKV-24) with activity against the chikungunya virus.
Note: This information has been fact-checked by healthcare providers.